CD1E encodes a specialized antigen-presenting molecule that functions in glycolipid recognition and presentation to immune cells. Unlike other CD1 family members, CD1E remains predominantly intracellular, accumulating in the Golgi apparatus of immature dendritic cells and late endosomes of mature dendritic cells, where it is cleaved to generate a soluble form 1. The soluble CD1E binds diacetylated lipids, including phosphatidyl inositides and sulfoglycolipids, which is essential for presenting these non-peptidic glycolipid antigens to CD1-restricted T cells 2. CD1E polymorphisms, particularly in exon 2, show significant ethnic variation and associate with autoimmune disease susceptibility. The CD1E*02/02 genotype correlates with increased risk of multiple sclerosis (OR 2.45) 2 and celiac disease (OR 2.93) 3, likely due to altered immune responses to lipid antigens. However, CD1E polymorphisms were not associated with Guillain-Barré syndrome susceptibility in Bangladeshi populations 4. Notably, the CD1E*02 allele is highly prevalent in Sub-Saharan Africans (87%) but rare in Europeans (36%), suggesting population-specific disease associations 5. CD1E expression positively correlates with dendritic cell populations and predicts favorable immunotherapy responses in cancer patients 6, indicating clinical relevance in both autoimmune and oncologic contexts.